San Francisco-based CRO Vial has strengthened its oncology expertise by adding oncologist Neeraj Agarwal, MD, to its scientific advisory board.
Vial announced the appointment earlier this month, predicting that Agarwal’s expertise in genitourinary cancer and experience conducting several clinical trials will be an asset. The firm wrote that it is “excited to work with brilliant minds like Dr. Agarwal who welcome a new approach to clinical trials”.
Agarwal was equally excited about the appointment, explaining that he will work to streamline Vial’s cancer drug trials.
“Over the past two decades, the entire process of conducting clinical trials has become exponentially cumbersome,” Agarwal said in a statement. critical to streamlining this process.”
Data from clinical trials is increasing demand for management technologies, says Medidata
Agarwal is currently the senior director of clinical research innovation at the Huntsman Cancer Institute at the University of Utah, as well as a consultant to the FDA’s Oncology Drug Advisory Committee. He also leads Early Therapy on the Genitourinary Cancer Committee of the SWOG Cancer Research Network.
His role at Vial will see Agarwal advise on the company’s oncology CRO, which was launched in June and will run alongside the dermatology and ophthalmology units the firm established earlier in the year.
Agarwal will work with existing advisors Guru Sonpavde, MD, Arati Rao, MD, and Antoni Ribas, MD, who joined Vial’s scientific board in June and July, respectively.
The expansion of Vial’s scientific board coincides with the launch of the latest version of Vial’s clinical trial management system, VialConnect. The new iteration of the software platform is designed to facilitate faster patient screening and recruitment by enabling clinics to identify potential trial participants.
- A new drug could change the scenario of stroke treatment, but a small Canadian biotech needs financial support
- Artificial intelligence predicts fall risk in lower limb amputees using 6-minute smartphone test: study
- Company born from Boston Children’s Hospital and ElevateBio will be based on new “regular” CAR-T stem cells
- US ramps up supply of monkeypox drugs as Nordic country of Bavaria boosts supply capacity via Grand River